Search Articles
Filter Articles
Found 1,741 articles
Alnylam Pharmaceuticals appoints Phil Davey as Country Manager, UK & Ireland
- 25 May 2022
Alnylam Pharmaceuticals has announced the appointment of Phil Davey as Country Manager of the UK and Ireland. Commenting on his appointment, Phil said: "I am delighted to have joined Alnylam as Country Manager for the UK and Ireland.
Beckley Psytech strengthens senior leadership team with appointment of Dr. Laura Trespidi as Chief Development Officer
- 25 May 2022
Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, has today announced the appointment of Dr. Laura Trespidi as Chief Development Officer.
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
- 25 May 2022
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and myNEO N.V., a Belgium-based immunotherapy company, today announced that they have entered into a research and option agreement.
PrecisionLife Wins Analytics Company of the Year at British Data Awards
- 25 May 2022
PrecisionLife Limited, an Oxford-based global techbio company generating deep insights into disease biology, is delighted to announce that it has been named a winner at the British Data Awards 2022. PrecisionLife was chosen by a prestigious panel of judges as the winner of Analytics Company of Year, for its unique AI and combinatorial analytics that is driving precision medicine in chronic diseases.
Artificial Intelligence to Advance NTCELL Production; Agreement Signed with Sydney-based start-up OptiCellAI
- 25 May 2022
Living Cell Technologies (ASX:LCT) is entering a new phase in its research, with artificial intelligence (AI) to be applied to the company’s groundbreaking research to combat Parkinson’s disease.
-
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
- 25 May 2022
In Eli Lilly and Company's (NYSE:LLY) pivotal, Phase 3 LUCENT-2 study, patients with ulcerative colitis (UC) who responded to mirikizumab at 12 weeks achieved and maintained statistically superior and clinically meaningful improvements at one year compared to placebo across the primary endpoint of clinical remission and all key secondary endpoints, including bowel urgency severity, using a novel, patient-reported outcome measure.
Thermo Fisher Scientific’s Clinical Research Business Receives ATD Award for Employee Talent Development
- 25 May 2022
The PPD clinical research business of Thermo Fisher Scientific has been recognized as one of the best in the world for its successful enterprise learning and development programs by the Association for Talent Development (ATD), a global organization that empowers professionals to develop talent in the workplace.
Siggi Olafsson to step down as Chief Executive
- 24 May 2022
Hikma Pharmaceuticals PLC (Hikma) today announces that Siggi Olafsson has resigned as Chief Executive Officer (CEO), and from Hikma’s Board of Directors, to pursue other opportunities.
Nouscom Announces Promotion of Richard Davis to Chief Operating Officer
- 24 May 2022
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced the promotion of Richard (Rick) Davis, PhD to Chief Operating Officer (COO) effective immediately. Rick joined Nouscom in September 2020 as Chief Business Officer.
Vaxzevria approved in the EU as third dose booster against COVID-19
- 24 May 2022
AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the European Medicine Agency (EMA) as a third dose booster in adults.
Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals
- 23 May 2022
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it has acquired Satiogen Pharmaceuticals, Inc., a San Diego-based company. Satiogen, now a wholly-owned Mirum subsidiary, was an existing licensing partner for LIVMARLI® (maralixibat) oral solution and volixibat.
PharmiWeb.Jobs Welcomes BTH Recruitment
- 23 May 2022
BTH Recruitment is totally focused on building a sought after, quality driven search and head hunting practice.
Top UK Pharma and Life Science Workplaces for Wellbeing (2022)
- 23 May 2022
In this article, we’ve rounded up the best Pharmaceutical and Life Science workplaces for well-being in the UK, based on the official rankings given by The Great Place to Work Institute in 2022.
Weekly Life Science News Round Up: 16th – 20th May
- 20 May 2022
A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 16th-20th May.
MAIA Biotechnology, Inc. Establishes Wholly Owned Subsidiaries in Romania and Australia to Support Global Development of THIO
- 20 May 2022
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that the company has established two wholly-owned subsidiaries in Romania and Australia to broaden and accelerate its global development plan for THIO, a telomere-targeting agent currently in development to evaluate its activity in multiple cancer indications.
Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies
- 19 May 2022
At a dedication today of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston’s Seaport, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced plans to build another 344,000 square foot facility in the Seaport to support the company’s continued rapid growth, in particular the expansion of its cell and genetic therapies programs.
7 Ways to Improve Your Job Advert SEO
- 19 May 2022
In the UK, the number of job vacancies has now exceeded the number of people unemployed for the first time, and similar trends are being seen across the globe. Making your job adverts stand out against so many others is becoming tougher than ever, yet it’s not an impossible challenge. In this article, we look at 7 ways to improve your job advert SEO, helping you to continue to attract the best talent in the Life Science industry.
Immutep appoints leading oncologists to its Clinical Advisory Board
- 19 May 2022
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announces today the appointment of four new members to the Company's Clinical Advisory Board (CAB).
MSD proud to be recognised as a family friendly workplace
- 18 May 2022
MSD has today been named a Family Friendly Workplace in accordance with the National Work + Family Standards. Established by UNICEF Australia and Parents at Work, the Family Friendly Workplaces certification framework encourages employers to benchmark their own internal standards against nationally recognised best practices.
